Lixiana®: The Effective Edoxaban Medication for Blood Clot Prevention

SAJA Pharmaceuticals from Saudi Arabia has introduced Lixiana®, a medication that effectively prevents blood clots in the brain and other blood vessels of the body. It is particularly useful for individuals with nonvalvular atrial fibrillation and at least one additional risk factor.

Uses and Dosage

Lixiana® is also used to treat blood clots in the veins of the legs and in the blood vessels of the lungs, as well as to prevent blood clots from re-occurring in the legs and/or lungs. The recommended dosage is one 60 mg tablet taken once daily, but adjustments may be made for individuals with impaired kidney function or a body weight of 60 kg or lower.

Contraindications

Lixiana® should not be taken by individuals who are allergic to edoxaban or any of its ingredients, actively bleeding, have a disease or condition that increases the risk of serious bleeding, are taking other medicines to prevent blood clotting, have a liver disease which leads to an increased risk of bleeding, have uncontrolled high blood pressure, or are pregnant or breastfeeding.

Precautions

It is important to talk to a doctor or pharmacist before taking Lixiana® if there is an increased risk of bleeding or if there are any concerns about the ability to drive or use machinery. Lixiana® is available in 15 mg, 30 mg, and 60 mg film-coated tablets.

Benefits of Lixiana®

Effective prevention of thrombosis in patients with nonvalvular atrial fibrillation and at least one additional risk factor
Treatment of blood clots in the veins and lungs, as well as prevention of re-occurrence
Adjustable dosage for individuals with impaired kidney function or a body weight of 60 kg or lower
Available in three different strengths: 15 mg, 30 mg, and 60 mg film-coated tablets
Suitable alternative to warfarin for patients who cannot tolerate it due to side effects or other reasons

Lixiana® is an anticoagulant medication that provides effective thrombosis prevention and treatment of cardiovascular diseases. It is an excellent alternative to warfarin, especially for those who are unable to tolerate its side effects or have contraindications.

Conclusion

SAJA Pharmaceuticals has developed Lixiana® as a reliable medication for blood clot prevention and treatment. With its active ingredient edoxaban, Lixiana® offers a safe and effective option for individuals with nonvalvular atrial fibrillation and at least one additional risk factor, vein thrombosis, pulmonary embolism, and other related conditions. Talk to your doctor or pharmacist about Lixiana® today!